GLP-1 Telehealth Scams in 2026: What to Watch For

The GLP-1 telehealth market is worth billions — and that kind of money attracts fraud. In 2026, the scam landscape has evolved from crude fake pharmacy websites to sophisticated operations that mimic legitimate telehealth platforms down to the intake forms and video consultation interfaces. Here's what to watch for, based on actual FDA enforcement actions and documented fraud patterns.

The Scale of the Problem

The FDA issued over 30 warning letters to GLP-1 telehealth companies in March 2026 alone — the second major wave following 55+ letters in September 2025. The violations weren't minor: companies were falsely implying their compounded products were equivalent to FDA-approved medications, obscuring pharmacy sourcing by marketing drugs under their own brand names, and making unsubstantiated efficacy claims.

FDA Commissioner Marty Makary described the enforcement as targeting companies that "mass-market compounded drugs" outside the legal framework. The Partnership for Safe Medicines reported that nearly half of online pharmacies offering semaglutide may be operating illegally, running non-delivery scams, or providing products that don't meet quality standards.

Beyond regulatory violations, outright criminal counterfeiting is increasing. The FDA has seized fake Ozempic pens containing unknown substances, and a growing number of Americans are buying unverified peptides directly from overseas manufacturers through social media — substances labeled "for research use only" that have no quality testing, no sterility assurance, and no regulatory oversight.

Scam Type 1: The Fake Pharmacy Website

These sites look like legitimate online pharmacies but have no actual pharmacy license, no prescribers on staff, and no real medication. You pay, and either nothing arrives, or you receive a vial containing an unknown substance. Some of these sites are sophisticated enough to include "tracking numbers" that lead to fake shipping portals.

How to spot it: No verifiable pharmacy license number. No prescriber names or NPI numbers. Prices dramatically below market ($30–50/month for "semaglutide"). Payment only via cryptocurrency, wire transfer, or gift cards. Domain registered within the last few months.

Scam Type 2: The "Research Chemical" Seller

These vendors sell substances labeled as semaglutide or tirzepatide marked "not for human consumption" or "for research use only." The products are typically sourced from overseas chemical suppliers — often Chinese API manufacturers — with no quality testing, sterility assurance, or regulatory oversight. Some are real peptides; some are degraded; some are entirely different substances.

How to spot it: "Research use only" disclaimers. No prescription required. Sold as lyophilized powder requiring reconstitution. Payment through non-standard channels. No US pharmacy involvement at any stage.

Scam Type 3: The Fake Telehealth Platform

The most dangerous category. These operations mimic the structure of legitimate telehealth companies — professional website, intake questionnaire, "consultation" with a supposed prescriber — but the clinical interaction is performative. The "prescriber" may not be licensed, the "pharmacy" may not exist, and the medication may be sourced from unverified suppliers.

The FDA specifically flagged platforms that obscure product sourcing by marketing medications under the telehealth company's own brand name without disclosing who actually compounded the medication. If the platform won't tell you which pharmacy prepared your medication, that's a significant risk signal.

How to spot it: No named prescribers. No named pharmacy partners. Unable to provide 503A or 503B registration documentation. "Consultation" is a brief questionnaire with no real-time interaction. Company was founded within the last year with no verifiable track record.

Scam Type 4: The Celebrity Deepfake Ad

The Better Business Bureau issued a specific alert about AI-generated celebrity endorsement videos promoting GLP-1 products on social media. Scammers create deepfake videos of celebrities like Oprah Winfrey and others appearing to endorse specific telehealth companies or GLP-1 products. The ads direct viewers to fraudulent checkout pages.

How to spot it: Celebrity endorsements for specific GLP-1 telehealth companies on social media. Urgency tactics ("limited supply," "offer expires today"). Links that go to checkout pages rather than legitimate company websites. No press releases or media coverage confirming the celebrity partnership.

Scam Type 5: The Bait and Switch

Some platforms advertise one price but charge a different amount once you've provided payment information. Others advertise compounded semaglutide but ship a "proprietary blend" that contains lower concentrations mixed with B12 or other fillers. The medication technically contains some semaglutide, but not at the dose prescribed.

How to spot it: Unclear ingredient lists. "Proprietary formulations" that don't disclose exact semaglutide or tirzepatide concentrations. Prices that change after you've signed up. Mandatory "add-ons" (supplements, coaching programs) that inflate the total cost beyond what was advertised.

How to Protect Yourself

The verification steps are consistent across all scam types: confirm the prescriber's state medical license, verify the pharmacy's 503A or 503B registration, check for LegitScript certification, look up the company on the BBB, and verify the business entity through the state Secretary of State's website. If any of these checks fail, don't proceed.

If you've already been scammed, report it to the FDA's MedWatch program (fda.gov/medwatch), the FTC (reportfraud.ftc.gov), your state Attorney General, and your bank or credit card company for a chargeback.

Platforms That Have Stood Up to Scrutiny